Recent studies indicated that IL-6 is the most consistently elevated cytokine in the blood of MDD patients, therefore it may serve as a predictive biomarker and a potential target to treat depression in humans (Hodes et al., 2016). This evidence concerns the gene IL6 and depressive symptom measurement.